Recurrent glomerulonephritis after renal transplantation

Chukwuma Chukwu, Rachel Middleton, Philip Kalra

Research output: Contribution to journalArticlepeer-review

247 Downloads (Pure)


Purpose of review
The current understanding of the incidence, predisposing factors, pathophysiology and effective treatment of recurrent glomerulonephritis (RGN) in renal transplants remains at best patchy and at worst, completely
lacking. Current reports have been limited by inconsistencies in study design, sample populations and lengths of follow-up. Making sense of the available evidence will provide the tools to support transplant nephrologists in their management of allograft donors and recipients.
Recent findings
With better survival of renal allografts, RGN has become a dominant factor influencing allograft survival. Evidently, the risk of recurrence is proportional to the incremental time posttransplantation. The proposed risk factors for RGN include but are not limited to the severity of primary glomerulonephritis (PGN),
younger recipient age, live-related donor allograft, minimal HLA mismatch, steroid avoidance and nonuse of induction therapy. Unfortunately, these findings are derived from retrospective cohort and registry studies; hence, true causality for RGN is hard to prove.
The management of RGN is improving, as we gain greater understanding of its pathophysiology, including the genetic, alloimmune and autoimmune contributions to recurrence. With better pretransplant risk stratification, posttransplant surveillance, novel biomarkers and new treatment strategies, we hope the transplant community will eventually have the tools to predict risk, prevent recurrence and personalise treatment of RGN.
Original languageEnglish
JournalCurrent Opinion in Nephrology & Hypertension
Issue number6
Publication statusPublished - 1 Nov 2020


Dive into the research topics of 'Recurrent glomerulonephritis after renal transplantation'. Together they form a unique fingerprint.

Cite this